Original Paper	Pharmacopsychiatry 2005; 38: 13-16 DOI: 10.1055/s-2005-837765
© Georg Thieme Verlag KG Stuttgart · New York
Fluoxetine Versus Trimipramine in the Treatment of Depression in Geriatric Patients
P. M. Wehmeier1, M. Kluge1, A. Maras2, D. Riemann3, M. Berger3, R. Kohnen4, R. W. Dittmann1,5, W. F. Gattaz6
1 Lilly Deutschland, Bad Homburg, Germany 2 Central Institute of Mental Health, Mannheim, Germany 3 Department of Psychiatry and Psychotherapy, University of Freiburg, Germany 4 IMEREM, Nuremberg, Germany 5 Psychosomatic Department, Children"s Hospital, University of Hamburg, Germany 6 Department of Psychiatry, Faculty of Medicine, University of São Paulo, Brazil

Introduction: Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), and trimipramine, a tricyclic antidepressant (TCA), were compared in terms of efficacy and tolerability in a six-week, parallel group, double-blind pilot study in 41 geriatric patients with major depression (61 - 85 years old). Method: The Hamilton Rating Scale for Depression (HAMD-17), the Montgomery-Asberg Rating Scale (MADRS), the Adjective Mood Scale (Bf-S), the Clinical Global Impression (CGI), and the Patients Global Impression (PGI) were used to measure changes in depressive symptoms. Results: Improvement with treatment was found on all scales. Efficacy and tolerability were similar in both groups. No statistically significant differences were found. Conclusion: These findings suggest that fluoxetine and trimipramine are comparable in terms of efficacy and tolerability in the treatment of major depression in geriatric patients.